Vanguard Group
SMMT icon

Vanguard Group’s Summit Therapeutics SMMT Stock Holding History

Vanguard Group’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$195M Sell
11,177,220
-202,508
-2% -$3.81M ﹤0.01% 1563
2025
Q3 		$235M Buy
11,379,728
+2,706,056
+31% +$65.6M ﹤0.01% 1464
2025
Q2 		$185M Sell
8,673,672
-2,966,835
-25% -$67.7M ﹤0.01% 1542
2025
Q1 		$225M Sell
11,640,507
-30,069
-0.3% -$603K ﹤0.01% 1430
2024
Q4 		$208M Buy
11,670,576
+724,040
+7% +$14M ﹤0.01% 1513
2024
Q3 		$240M Buy
10,946,536
+2,128,073
+24% +$29.8M ﹤0.01% 1449
2024
Q2 		$68.8M Buy
8,818,463
+1,549,220
+21% +$8.37M ﹤0.01% 2018
2024
Q1 		$30.1M Buy
7,269,243
+254,261
+4% +$1.01M ﹤0.01% 2394
2023
Q4 		$18.3M Buy
7,014,982
+919,307
+15% +$1.89M ﹤0.01% 2639
2023
Q3 		$11.4M Sell
6,095,675
-4,815
-0.1% -$9.18K ﹤0.01% 2815
2023
Q2 		$15.3M Buy
6,100,490
+4,635,361
+316% +$8.46M ﹤0.01% 2710
2023
Q1 		$2.56M Buy
1,465,129
+21,571
+1% +$58.8K ﹤0.01% 3587
2022
Q4 		$6.14M Buy
1,443,558
+667,636
+86% +$1.21M ﹤0.01% 3204
2022
Q3 		$923K Hold
775,922
– – ﹤0.01% 4026
2022
Q2 		$776K Sell
775,922
-135,474
-15% -$190K ﹤0.01% 4166
2022
Q1 		$2.23M Buy
911,396
+4,509
+0.5% +$11.4K ﹤0.01% 3911
2021
Q4 		$2.44M Buy
906,887
+1,357
+0.1% +$6.52K ﹤0.01% 3969
2021
Q3 		$4.54M Buy
905,530
+25,632
+3% +$184K ﹤0.01% 3724
2021
Q2 		$6.56M Buy
879,898
+330,356
+60% +$2.17M ﹤0.01% 3440
2021
Q1 		$3.23M Hold
549,542
– – ﹤0.01% 3734
2020
Q4 		$2.58M Buy
+549,542
New +$2.33M ﹤0.01% 3594

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PCMH
Polymer Capital Management (HK) Hong Kong $1.98B AUM 210.13% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Vanguard Group's SMMT Position: Q4 2025 in Review

Vanguard Group reduced its Summit Therapeutics (SMMT) stake by 1.8% in Q4 2025, selling an estimated $3.81M and leaving 11,177,220 shares worth $195M. The position accounts for ﹤0.01% of the portfolio, ranked #1563.

Vanguard Group first reported a position in SMMT in Q4 2020 and has held it in 21 quarters since. The position peaked at $240M in Q3 2024. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

  • Vanguard Group held 11,177,220 shares of Summit Therapeutics worth $195M as of Q4 2025.
  • Vanguard Group sold 202,508 Summit Therapeutics shares in Q4 2025, an estimated $3.81M.
  • Summit Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1563 holding.
  • Vanguard Group first reported a position in Summit Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Vanguard Group's Summit Therapeutics position peaked at $240M in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.